JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Gossamer Bio Inc

Cerrado

SectorSanidad

2.35 -2.08

Resumen

Variación precio

24h

Actual

Mínimo

2.27

Máximo

2.39

Métricas clave

By Trading Economics

Ingresos

-1.6M

-38M

Ventas

1.6M

11M

Margen de beneficios

-333.127

Empleados

144

EBITDA

-1.8M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+311.29% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

25M

520M

Apertura anterior

4.43

Cierre anterior

2.35

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

119 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct 2025, 23:25 UTC

Ganancias

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct 2025, 23:18 UTC

Ganancias

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct 2025, 22:20 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct 2025, 22:13 UTC

Ganancias

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct 2025, 21:38 UTC

Ganancias

Correction to Visa Sales Jump Article

28 oct 2025, 21:17 UTC

Ganancias

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct 2025, 21:07 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct 2025, 21:02 UTC

Ganancias

Mondelez Tempers Outlook as Costs Rise

28 oct 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct 2025, 23:02 UTC

Ganancias

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct 2025, 23:01 UTC

Ganancias

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct 2025, 22:46 UTC

Ganancias

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct 2025, 22:45 UTC

Ganancias

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct 2025, 22:44 UTC

Ganancias

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct 2025, 22:43 UTC

Ganancias

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct 2025, 22:42 UTC

Ganancias

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct 2025, 22:20 UTC

Ganancias

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct 2025, 22:02 UTC

Ganancias

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct 2025, 21:20 UTC

Ganancias

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct 2025, 21:19 UTC

Ganancias

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct 2025, 21:18 UTC

Ganancias

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

311.29% repunte

Estimación a 12 Meses

Media 10.2 USD  311.29%

Máximo 15 USD

Mínimo 8 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

119 / 373 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat